Want to join the conversation?
Drug maker $REGN said Sarilumab, the company's IL-6 receptor antibody for treatment of rheumatoid arthritis is under review with the FDA. Dupilumab is being developed for a number of indications and $REGN is targeting completion of its BLA submission for moderate-to-severe atopic dermatitis in 3Q16.
Seems like $AMD has hit the right wind. Its stock was up almost 9% to $9.45 on Tuesday following reports that it signed a licensing deal with Intel.
$SBUX launched its annual “Starbucks for Life” competition in the U.S. and Canada. The winner of the competition will receive a credit of one drink or food item per day for a duration of 30 years.
$T shares rose 1.8%, as a big boost for the S&P 500. The company said its new streaming television service DirectTV has so far exceeded expectations.
$TXMD flying high.. anyone here to catch..?